MAPT and Alzheimer disease: The primary biomarkers used in detecting and monitoring AD include beta-amyloid and tau proteins, which are typically measured in cerebrospinal fluid (CSF), along with imaging biomarkers such as PET scans for assessing beta-amyloid burden and MRI scans for detecting changes in brain volume.